Vor Biopharma Inc.
Close on Oct 19, 2026
- Market cap
- $979.65M
- P/E (TTM)
- –
- Dividend yield
- –
About Vor Biopharma
Biological Products, (No Diagnostic Substances), SIC 2836
Vor Biopharma Inc. is a clinical-stage biopharmaceutical company that develops therapies for autoimmune diseases. Its primary product candidate is telitacicept, a novel fusion protein designed to inhibit B cell lymphocyte stimulator and a proliferation-inducing ligand. By targeting these signaling molecules, the therapy reduces autoimmune responses driven by B cells. The company develops treatments for chronic conditions such as generalized myasthenia gravis and Sjögren’s disease, aiming to serve patients suffering from these neuromuscular and autoimmune illnesses.
Vor Biopharma conducts clinical development programs internationally, maintaining clinical trial sites across the United States, Europe, South America, and Asia. The company holds exclusive rights to develop and commercialize telitacicept in territories outside of Greater China. Its principal executive offices are located in Boston, Massachusetts.
Summary of the business section of Vor Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vor Biopharma Inc.
- Headquarters
- Boston, MA
- Address
- 500 Boylston Street, Suite 1350 02116
- Phone
- (617) 655-6580
- Website
- vorbio.com
- Employees
- 76, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- VOR
- Exchange
- Nasdaq
- IPO date
- Feb 8, 2021
- Shares outstanding
- 59M, Aug 6, 2026
- Public float
- $76.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Sep 19, 2025; 1-for-20 reverse, Jun 30, 2025
- SEC CIK
- 1817229
- CUSIP
- 929033207
- ISIN
- US9290332074
- EIN
- 81-1591163
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jean-Paul Kress | CEO and Chairman, Director | – |
| Robert Ang | PRESIDENT AND CEO, Director | 911,318 |
| Jeremy Brett Sokolove | Chief Medical Officer | 27,900 |
| Qing Che Zuraw | Chief Development Officer | 937,080 |
| Sandesh Mahatme | CFO | 0 |
| Tirtha Chakraborty | Chief Sci Off & Head Tech Ops | 217,416 |
| Han Wook Choi | Chief Financial Officer | 51,280 |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | 126,625 |
| Amy Quinlan | Vice President of Finance | 50,312 |
| David Zaccardelli | Director | – |
| Wouter Joustra | Director | – |
| Daniella Beckman | Director | – |
| Michel Detheux | Director | – |
| Andrew David Levin | Director | – |
| Alexander Cumbo | Director | – |
| Erez Kalir | Director | – |
| Fouad Namouni | Director | – |
| RA Capital Nexus Fund, L.P. | Director | 1,401,226 |
| Sarah Burgess Reed | Director | – |
| Joshua Resnick | Director | – |
| Sven Ante Lundberg | Director | 29,432 |
| David Charles Lubner | Director | – |
| Matthew R. Patterson | Director | 41,196 |
Employees
Headcount reported in annual reports
“As of March 3, 2026, we had 76 full-time employees, 19 of whom held an M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 25, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 30, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 8, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 1, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |